Sell to close the June 15, 2018 call on Abbvie (NYSE: ABBV) with a strike price of $105 at $4.20 or higher for a swift 50% gain. Symbol (ABBV180615C105). It’s a beautiful thing when an options trade suggestion works out almost exactly as planned. Abbvie boosted investor confidence regarding… Read More
Linda McDonough is a veteran hedge fund analyst who loves to break down company financial statements and identify market inefficiencies to uncover big opportunities. She believes in a boots-on-the-ground approach that includes surveying customers, interviewing company executives, or doing whatever it takes to see what others don't.
She's now brought her experience as a hedge fund analyst to subscribers of her Profit Catalyst Alert service. Her system identifies small- and mid-cap stocks that are about to move due to catalytic events that few others can identify...until it's too late. These events often times result in massive gains for her followers.
Analyst Articles
Sell Celgene as the stock has closed below its $83 stop loss limit for two consecutive days. Despite decent news, the stock continues to drop. Read More
Walmart is selling off due to its super pricey entry into the Indian market. Book this significant gain in the June puts. Read More
Harsco's surge in demand began even before the government's policy changes on aluminum and steel and what Abbvie's Dutch tender means for investors. Read More
Buy Abbvie ahead of a May 9th conference when investors will hear more about its recent surprising success in its new Hep C drug. Read More
Old Dominion Freight and SAIA, both less than truckload shippers, saw earnings rise on higher rates and increased volume of shipments. Investors, nervous about the sustainability of the global economy sold the stocks off a bit, unjustifiably, I believe. PRA redeemed itself with a strong backlog and more. Read More
Improvements from Synchrony's tighter lending standards and a partnership with juggernaut PayPal should drive earnings higher. Read More
Despegar.com is capitalizing on the growing Latin American travel market. A rare combination of exploding growth and expanding margins are propelling earnings. Read More
Some spring cleaning resulted in three names being sold from the portfolio due to lack of catalysts. New names are taking root and the news abounds for current holdings. Why Ichor got hit so hard last week and more... Read More
Vulcan is down 9% since my January 2016 recommendation. The hype surrounding new government infrastructure dollars has yet to translate into significant earnings momentum at Vulcan. The stock is likely to drift without a near-term catalyst. Read More